Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
In 2025, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study, “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” The […]